Published in Vaccine Weekly, October 23rd, 2002
In the studies conducted by independent French laboratories, GenOdyssee's variants demonstrated up to 1 hundred times greater efficacy compared with IFN alpha molecules currently on the market.
Michael Tovey, director of the Viral Oncology Laboratory at CNRS Research Institute (French National Center for Scientific Research) commented, "GenOdyssee's interferons display excellent toxicity profiles and are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly